New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 (opens original article in a new tab)

New study data show Takeda's oveporexton improved daily function, cognition, and sleep for narcolepsy type 1 patients, with regulatory submissions underway.

• Oveporexton improved daily functioning, cognition, and nighttime sleep in narcolepsy type 1 patients.
• Secondary and exploratory endpoints from Phase 3 studies showed significant symptom improvements.
• Takeda is seeking regulatory approval for oveporexton as the first orexin agonist for NT1.